Đang chuẩn bị liên kết để tải về tài liệu:
Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Docetaxel was used to treat metastatic CRPC patients. However, Doc resistance in prostate cancer (PCa) hinders its clinical application. | Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells

TÀI LIỆU LIÊN QUAN

DNA methylation of miR-138 regulates cell proliferation and EMT in cervical cancer by targeting EZH2

Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells